Generation of Stable cisPt Resistant Lung Adenocarcinoma Cells

• मुख्य लेखकों: Nico Ruprecht (लेखक), Lukas Hofmann (लेखक), Martin Nils Hungerbühler (लेखक), Christoph Kempf (लेखक), Johannes Thomas Heverhagen (लेखक), Hendrik von Tengg-Kobligk (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: MDPI AG, 2020-05-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.
• Notes: 10.3390/ph13060109; 1424-8247
• Keywords: cisplatin; NSCLC; lung cancer; VRAC; resistance; Medicine; R; Pharmacy and materia medica; RS1-441
• Source: Pharmaceuticals, Vol 13, Iss 6, p 109 (2020)

Platinum compounds represent the backbone of combined chemotherapy protocols for advanced lung cancer. The mechanisms responsible for its frequent primary or acquired resistance to cisplatin (cisPt)-based chemotherapy remains enigmatic. The availability of two cell lines of the same origin, one resistant and the other sensitive, will facilitate research to reveal the mechanism of resistance formation. Lung adenocarcinoma cells, A240286S (A24), were cultivated in increasing cisPt concentrations over a prolonged time. After a significant increase in IC₅₀ was measured, cultivation of the cells was continued in absence of cisPt and IC₅₀s determined over a long period (>7 months). As a result, a cell line with lasting, high-level cisPt resistance, designated (D-)A24cisPt8.0, was obtained. The cells were cross-resistant to oxaliplatin and to pemetrexed at a low level. Previous publications have claimed that Leucine-rich repeat-containing protein 8 (LRRC8A and LRRC8D) of the volume-regulated anion channels (VRACs) affect cellular resistance to cisPt. Even though cisPt decreased LRRC8D expression levels, we showed by knockdown and overexpression experiments with LRRC8A and D that these proteins do not govern the observed cisPt resistance. The tumor cell sublines described here provide a powerful model to study the mechanisms of resistance to cisPt in lung cancer cells and beyond.